CNBX Pharmaceuticals Inc. (CNBX)
USD 0.01
(5.93%)
USD 0.01
(5.93%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 499.03 Thousand USD | -38.48% |
| 2022 | 811.16 Thousand USD | -73.65% |
| 2021 | 3.07 Million USD | 38.73% |
| 2020 | 2.21 Million USD | -85.38% |
| 2019 | 15.18 Million USD | 376.72% |
| 2018 | 3.18 Million USD | -12.45% |
| 2017 | 3.63 Million USD | 15238.83% |
| 2016 | 23.71 Thousand USD | -17.38% |
| 2015 | 28.7 Thousand USD | -99.37% |
| 2014 | 4.52 Million USD | 6118.3% |
| 2013 | 72.75 Thousand USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | -100.0% |
| 2010 | 94.96 Thousand USD | -46.57% |
| 2009 | 177.74 Thousand USD | -39.04% |
| 2008 | 291.56 Thousand USD | -8.12% |
| 2007 | 317.32 Thousand USD | 84.99% |
| 2006 | 171.54 Thousand USD | 541.08% |
| 2005 | 26.75 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 80.02 Thousand USD | -51.18% |
| 2024 Q1 | 387.4 Thousand USD | -22.37% |
| 2024 Q2 | 163.91 Thousand USD | -57.69% |
| 2023 Q3 | 662.01 Thousand USD | 43.28% |
| 2023 Q1 | 609.5 Thousand USD | -24.86% |
| 2023 Q4 | 499.03 Thousand USD | -24.62% |
| 2023 FY | 499.03 Thousand USD | -38.48% |
| 2023 Q2 | 462.05 Thousand USD | -24.19% |
| 2022 Q1 | 2.12 Million USD | -31.14% |
| 2022 FY | 811.16 Thousand USD | -73.65% |
| 2022 Q2 | 1.13 Million USD | -46.33% |
| 2022 Q3 | 965.74 Thousand USD | -15.12% |
| 2022 Q4 | 811.16 Thousand USD | -16.01% |
| 2021 Q4 | 3.07 Million USD | -19.02% |
| 2021 Q2 | 4.96 Million USD | 192.4% |
| 2021 Q1 | 1.69 Million USD | -23.47% |
| 2021 FY | 3.07 Million USD | 38.73% |
| 2021 Q3 | 3.8 Million USD | -23.45% |
| 2020 Q2 | 3.57 Million USD | -44.73% |
| 2020 Q1 | 6.46 Million USD | -57.44% |
| 2020 Q3 | 5.52 Million USD | 54.8% |
| 2020 Q4 | 2.21 Million USD | -59.85% |
| 2020 FY | 2.21 Million USD | -85.38% |
| 2019 Q4 | 15.18 Million USD | -23.21% |
| 2019 Q1 | 9.48 Million USD | 197.76% |
| 2019 Q2 | 18.34 Million USD | 93.44% |
| 2019 FY | 15.18 Million USD | 376.72% |
| 2019 Q3 | 19.77 Million USD | 7.78% |
| 2018 Q2 | 3.72 Million USD | 21.59% |
| 2018 Q4 | 3.18 Million USD | 0.8% |
| 2018 FY | 3.18 Million USD | -12.45% |
| 2018 Q1 | 3.06 Million USD | -15.84% |
| 2018 Q3 | 3.15 Million USD | -15.12% |
| 2017 Q4 | 3.63 Million USD | 5.05% |
| 2017 Q3 | 3.46 Million USD | 485.29% |
| 2017 Q2 | 591.64 Thousand USD | 109.09% |
| 2017 Q1 | 282.95 Thousand USD | 1093.11% |
| 2017 FY | 3.63 Million USD | 15238.83% |
| 2016 Q3 | 92.5 Thousand USD | 9.76% |
| 2016 FY | 23.71 Thousand USD | -17.38% |
| 2016 Q4 | 23.71 Thousand USD | -74.36% |
| 2016 Q1 | 277.79 Thousand USD | 867.8% |
| 2016 Q2 | 84.28 Thousand USD | -69.66% |
| 2015 Q3 | 4.43 Million USD | -0.45% |
| 2015 FY | 28.7 Thousand USD | -99.37% |
| 2015 Q1 | 4.49 Million USD | -0.57% |
| 2015 Q2 | 4.45 Million USD | -0.86% |
| 2015 Q4 | 28.7 Thousand USD | -99.35% |
| 2014 Q3 | - USD | -100.0% |
| 2014 FY | 4.52 Million USD | 6118.3% |
| 2014 Q4 | 4.52 Million USD | 0.0% |
| 2014 Q1 | 31.35 Thousand USD | -56.91% |
| 2014 Q2 | 1076.00 USD | -96.57% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 FY | 72.75 Thousand USD | 0.0% |
| 2013 Q4 | 72.75 Thousand USD | 519578.57% |
| 2013 Q3 | 14.00 USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2011 Q4 | - USD | -100.0% |
| 2011 Q1 | 94.96 Thousand USD | 0.0% |
| 2011 Q3 | 2.08 Million USD | 1940.2% |
| 2011 Q2 | 102.22 Thousand USD | 7.65% |
| 2011 FY | - USD | -100.0% |
| 2010 FY | 94.96 Thousand USD | -46.57% |
| 2010 Q4 | 94.96 Thousand USD | -19.85% |
| 2010 Q3 | 118.48 Thousand USD | -35.53% |
| 2010 Q2 | 183.77 Thousand USD | 14.84% |
| 2010 Q1 | 160.02 Thousand USD | -9.97% |
| 2009 Q1 | 290.33 Thousand USD | -0.42% |
| 2009 FY | 177.74 Thousand USD | -39.04% |
| 2009 Q4 | 177.74 Thousand USD | -37.37% |
| 2009 Q3 | 283.77 Thousand USD | -0.46% |
| 2009 Q2 | 285.07 Thousand USD | -1.81% |
| 2008 Q4 | 291.56 Thousand USD | -4.84% |
| 2008 Q3 | 306.38 Thousand USD | -0.65% |
| 2008 Q2 | 308.39 Thousand USD | -2.52% |
| 2008 Q1 | 316.37 Thousand USD | -0.3% |
| 2008 FY | 291.56 Thousand USD | -8.12% |
| 2007 Q1 | 359.92 Thousand USD | 109.82% |
| 2007 Q2 | 349.86 Thousand USD | -2.8% |
| 2007 FY | 317.32 Thousand USD | 84.99% |
| 2007 Q3 | 346 Thousand USD | -1.1% |
| 2007 Q4 | 317.32 Thousand USD | -8.29% |
| 2006 Q1 | 25.43 Thousand USD | 0.0% |
| 2006 Q4 | 171.54 Thousand USD | 829.66% |
| 2006 Q3 | 18.45 Thousand USD | 0.0% |
| 2006 Q2 | 18.45 Thousand USD | -27.46% |
| 2006 FY | 171.54 Thousand USD | 541.08% |
| 2005 FY | 26.75 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -21503.42% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 74.515% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 95.272% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | 9.614% |
| Rebus Holdings, Inc. | 5000.00 USD | -9880.78% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.617% |
| Qrons Inc. | 420.00 USD | -118718.81% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | 35.244% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 98.214% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -3.846% |
| Skye Bioscience, Inc. | 11.94 Million USD | 95.821% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 98.715% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 93.088% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -553.586% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.534% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 65.152% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -589.614% |
| Mesoblast Limited | 667.9 Million USD | 99.925% |
| Marizyme, Inc. | 22.01 Million USD | 97.733% |
| Genus plc | 1.02 Billion USD | 99.951% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 63.261% |
| Pharming Group N.V. | 462.85 Million USD | 99.892% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 84.937% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | 20.408% |
| ContraFect Corporation | 20.67 Million USD | 97.587% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -27.839% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -30.578% |
| IMV Inc. | 31.33 Million USD | 98.407% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 87.963% |
| MultiCell Technologies, Inc. | 126.22 USD | -395272.366% |
| ONE Bio Corp. | 70.08 Million USD | 99.288% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 46.893% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.612% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -15.595% |
| Q BioMed Inc. | 3.51 Million USD | 85.805% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 98.581% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -91.0% |
| Biomind Labs Inc. | 73.81 Thousand USD | -576.031% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.888% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 65.556% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 98.337% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 81.829% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | 27.411% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 80.83% |
| GB Sciences, Inc. | 103.44 Thousand USD | -382.434% |
| Alpha Cognition Inc. | 2.45 Million USD | 79.649% |
| HST Global, Inc. | 1526.00 USD | -32602.425% |
| CSL Limited | 38.02 Billion USD | 99.999% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 49.488% |
| Halberd Corporation | 10.13 Thousand USD | -4825.861% |
| Enzolytics Inc. | 361.7 Million USD | 99.862% |
| Agentix Corp. | 261.39 Thousand USD | -90.916% |
| Resverlogix Corp. | 8.11 Million USD | 93.85% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 73.425% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.989% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 98.954% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | 21.983% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -2090.593% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 94.424% |
| AVAX Technologies, Inc. | 7.37 Million USD | 93.235% |
| Zenith Capital Corp. | 7410.00 USD | -6634.669% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.985% |
| Ember Therapeutics, Inc. | 184.00 USD | -271116.848% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -55.074% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -90.936% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 46.222% |
| Kadimastem Ltd | 2.3 Million USD | 78.341% |
| Helix BioMedix, Inc. | 3.02 Million USD | 83.503% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 99.053% |
| BioStem Technologies, Inc. | 14.56 Million USD | 96.573% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -774.066% |
| LadRx Corporation | 2.3 Million USD | 78.377% |
| Cell Source, Inc. | 195.17 Thousand USD | -155.693% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -41.124% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -41.124% |
| NovAccess Global Inc. | 62.24 Thousand USD | -701.695% |
| Affymax, Inc. | 7.44 Million USD | 93.295% |
| Itoco Inc. | 1.4 Million USD | 64.356% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -421.696% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -370.792% |
| Mobile Lads Corp. | 52.00 USD | -959590.385% |
| CytoDyn Inc. | 11.13 Million USD | 95.519% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -249.047% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -2691.046% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -29.462% |
| SYBLEU INC | 330.46 Thousand USD | -51.01% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -21.889% |
| International Stem Cell Corporation | 5.39 Million USD | 90.741% |
| Bioxytran, Inc. | 137.63 Thousand USD | -262.574% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 96.673% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 96.99% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -531.695% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | 42.286% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 93.361% |
| Neutra Corp. | 2851.00 USD | -17403.999% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 98.46% |
| PureTech Health plc | 693.97 Million USD | 99.928% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 93.817% |
| IXICO plc | 15.84 Million USD | 96.85% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 93.974% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.517% |
| CSL Limited | 38.02 Billion USD | 99.999% |
| Cellectis S.A. | 333.99 Million USD | 99.851% |